Clinical Characteristics and Mechanisms of Acute Myocarditis.
Stephane Heymans, Sophie Van Linthout, Sarah Mignon Kraus...
https://pubmed.ncbi.nlm.nih.gov/38963866/Actively Recruiting
Led by Massachusetts General Hospital · Updated on 2026-08-20
390
Participants Needed
31
Research Sites
26 weeks
Total Duration
Researchers are investigating whether abatacept, compared to a placebo, can reduce major adverse cardiac events MACE in patients hospitalized with myocarditis caused by immune checkpoint inhibitors ICI. This condition is a rare but serious side effect of ICI cancer treatments, and current corticosteroid therapies still result in a high rate of cardiac complications. The trial aims to provide clearer evidence on abatacepts potential benefits in this setting through a randomized, double-blind, placebo-controlled phase 3 study. Participants receive up to four intravenous doses of abatacept at 10 mgkg or placebo, given at randomization, 24 hours later, at 14 days, and optionally at 28 days. All participants continue standard care including corticosteroids. The study compares abatacept plus standard care with placebo plus standard care. The trial is conducted with careful monitoring of cardiac events and safety outcomes over six months. During the study, participants are hospitalized at randomization and undergo regular assessments including monitoring of heart function, blood tests for markers like troponin, and clinical status evaluations. The main outcome is the occurrence of major cardiac events within six months. Secondary measures include illness severity scales, additional cardiac markers, and immune-related side effects. The study also tracks adverse events and overall patient health throughout the trial period.
CONDITIONS
Abatacept in Immune Checkpoint Inhibitor Myocarditis
H
Hannah K Gilman, MS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Massachusetts General Hospital
Lead Sponsor
Bristol-Myers Squibb
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Abatacept + standard of care | Placebo + standard of care | High‑dose steroids alone |
|---|---|---|---|
| What it is | Abatacept added to corticosteroids as an investigational treatment arm in hospitalized patients with ICI‑associated myocarditis | Placebo plus corticosteroids as the control arm in the randomized trial | High‑dose corticosteroids alone are current standard first‑line treatment for ICI‑associated myocarditis |
| Role in trial | Investigational treatment arm receiving abatacept plus steroids | Control arm receiving placebo plus steroids | Not part of the trial, represents current practice outside of trial |
| Primary use | Treatment of hospitalized patients with ICI‑associated myocarditis | Treatment comparator arm in heroinics with ICI‑associated myocarditis | Standard first‑line therapy for ICI‑associated myocarditis |
| How administered/performed | Abatacept infusions given intravenously alongside standard‑dose corticosteroids | Placebo infusions alongside standard‑dose corticosteroids | High‑dose intravenous corticosteroids alone per institutional protocols |
| Evidence maturity | Efficacy under evaluation in a randomized phase III trial | Comparator arm efficacy being defined by trial outcome | High‑dose steroids are regarded as first‑line treatment based on case series and reviews |
| Important risks | Unknown; investigational arm safety data not yet established | Safety risks reflect steroid‑related adverse effects plus trial‑specific risks | High‑dose steroids carry known risks including infection, glucose intolerance and bone loss |
| Important limitations | Efficacy and safety outcomes are not yet available from this ongoing trial | Compare outcomes only once trial completes; placebo arm not usable as current‑care comparator outside trial | Evidence is based on observational data and case series rather than randomized comparisons |
| Patient‑relevant outcomes | Not yet known; trial will assess MACE and troponin outcomes | Not yet known until trial results report | High‑dose steroids have been associated with reduced major cardiac events in observational series |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - 28 days
Participants receive up to four intravenous infusions of abatacept or placebo alongside standard corticosteroid care.
Infusions at day 0, 1, 14, and optional at day 28
Duration - 6 months
Participants are monitored for major adverse cardiac events and other outcomes for six months after treatment starts.
Regular assessments during follow-up period
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Stephane Heymans, Sophie Van Linthout, Sarah Mignon Kraus...
https://pubmed.ncbi.nlm.nih.gov/38963866/Massachusetts General Hospital
Lead Sponsor
Bristol-Myers Squibb
Collaborating Sponsor